Alexion Pharma (ALXN) Announces Restructuring, Including Workforce Reduction of 20%

Alexion Pharma (ALXN) Announces Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results show sustained treatment benefits across a range of MG-specific assessment scales through an additional 52 weeks for patients who continued to receive Soliris, and also demonstrate rapid, significant and sustained improvements through 52 weeks for patients who had crossed over from placebo in REGAIN to Soliris treatment in... More

Alexion Pharmaceuticals (ALXN) PT Raised to $158 at Deutsche Bank Following Restructuring News

Deutsche Bank raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158.00 (from $153.00) while maintaining a Buy rating following the company's restructuring announcement.

Analyst... More

Alexion Pharmaceuticals (ALXN) PT Raised to $182 at Leerink Partners

Leerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $182.00 (from $170.00) while maintaining a Outperform rating following yesterday's reconstructing news.

Analyst Geoffrey Porges sees more good news to come, gMG Plus leverage offers upside.

Alexion Pharmaceuticals (ALXN) PT Raised to $180 at SunTrust Robinson Humphrey

SunTrust Robinson Humphrey analyst Yatin Suneja raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $180.00 (from $170.00) while maintaining a Buy rating after the company announced a restructuring to re-align the company with its previously announced strategic plan.

Suneja commented, "While today's... More

Alexion Pharmaceuticals (ALXN) PT Raised to $173 at BMO Capital

BMO Capital analyst M. Ian Somaiya raised his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $173.00 (from $168.00) while maintaining a Outperform rating as the company's plan to cut 20% of its workforce leading to $250mn annual savings was foreshadowed by prior guidance of non-GAAP operating... More

Alexion Pharma (ALXN) to Host Call to Discuss Restructuring Tomorrow

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.m. ET. Following the release, Alexion management will conduct a conference call and audio webcast on... More